ARCHIVES

Volasertib and LDAC Doubled Response in Older Patients

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

DCT Board Okays Contract Recompetitions, But Litton Bionetics May Be Barred From Two Supporting Gall’s Lab, Plus FCRF Program

November 1, 1985

Antigenics Begins Phase II Trial Of Oncophage for NHL.

March 31, 2000

AACR Membership Up 14 Percent Per Year Since ‘88

June 8, 1990

NCI Initiatives: Advisors Approves AIDS, Minority Training Programs

December 13, 1996

In Brief: David Feigal To Head FDA’s Antiviral Division; ODAC To Discuss Melphalan, Amifostine NDAs

January 17, 1992

Gleevec Approval Sets Record For FDA Review: 73 Days

May 25, 2001